Natera, Inc.
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Clinical MRD Oncology Tests Processed by Year
Clinical MRD Oncology Tests Processed — Annual Exact Count (tests)
Natera Clinical MRD Oncology Tests Processed: 769,700.00 tests in FY2025, up 54.5% from a year earlier.
Where the FY2025 figure comes from
“Approximately 800,800 oncology tests, including approximately 769,700 clinical MRD tests, were processed in the full year 2025 compared to 528,200 oncology tests, including 498,300 clinical MRD tests, in the full year 2024, an increase of 52%.”
Source: Form 8-K Ex 99.1 (2026-01-12) ↗
Full-year exact clinical MRD oncology test count disclosed in Form 10-K MD&A (360,200 in FY2023; 525,700 in FY2024; 769,700 in FY2025).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Clinical MRD Oncology Tests Processed — Annual Exact Count (tests) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 769,700.00 | +54.5% | Form 8-K Ex 99.1 (2026-01-12) ↗ |
| FY2024 | Dec 31, 2024 | 498,300.00 | +63.2% | Form 8-K Ex 99.1 (2025-01-13) ↗ |
| FY2023 | Dec 31, 2023 | 305,400.00 | – | Form 8-K Ex 99.1 (2025-01-13) ↗ |
Cite this data
StockData. (2026). Natera Clinical MRD Oncology Tests Processed, annual FY2023–FY2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/vol-clinical-mrd-oncology-fy
See every metric in the Natera KPI table. Data updated Nov 2, 2026.